๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreatic Neoplasms
Clinical trial register · China

Pancreatic Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 8 Tianjin 2 Wuhan 1 Beijing 1 Guangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai8 Tianjin2 Wuhan1 Beijing1 Guangzhou1
All 9 locations
Target enrolment
to

Pancreatic Neoplasms trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
NCT07791550Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-08-28
Not yet open
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
NCT07796906Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms
Tianjin Medical University Cancer Institute and Hospital
Not applicable
320
Tianjin
2026-08-28
Recruiting
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
NCT07504471Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
Phase 2
50
Shanghai
2026-03-23
Not yet open
22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
NCT07012694Pancreatic Neoplasms, Mediastinal Neoplasms, Abdominal Neoplasm, Excluding Pancreas Neoplasm
Huazhong University of Science and Technology
Not applicable
576
Wuhan
2025-07
Recruiting
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674Pancreatic Neoplasms
Fudan University
Phase 2
30
Shanghai
2025-03-20
Recruiting
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
NCT06577532Pancreatic Neoplasms, Other Solid Tumors
Ruijin Hospital
Phase EARLY_PHASE1
56
Shanghai
2024-09-24
Recruiting
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
NCT06532617Pancreatic Neoplasms
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
30
Shanghai
2024-09-19
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
NCT05737953Pancreatic Neoplasms, DNA Methylation, Proteome
Zhaoshen Li
Observational
100
Shanghai
2023-03-01
Active, closed
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT05481476Pancreatic Neoplasms
Sun Yat-sen University
Phase 2
32
Guangzhou
2022-12-12
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
Changhai Hospital
Phase 1/2
30
Shanghai
2021-10-21
Recruiting
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
Chinese PLA General Hospital
Phase 1/2
90
Beijing
2021-08-04
By invitation
The Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
NCT06685939Pancreatic Neoplasms
Zhijun Bao
Observational
220
Shanghai
2020-01-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/pancreatic-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Pancreatic Neoplasms.

How many Pancreatic Neoplasms trials are recruiting in China?

8 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Neoplasms), 13 studies
PhaseStudiesRecruitingShare
Phase 25438.5%
Not applicable3023.1%
Observational2115.4%
Phase 1/22215.4%
Phase EARLY_PHASE1117.7%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Neoplasms)
Lead sponsorStudiesRecruiting
Ruijin Hospital22
Tianjin Medical University Cancer Institute and Hospital20
Changhai Hospital11
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Chinese PLA General Hospital11
Fudan University11
Huazhong University of Science and Technology10
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine11
Sun Yat-sen University10
Zhaoshen Li11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.